SCHEMBL9000147

SCHEMBL9000147

NC1=NN(c2ccc(S(=O)(=O)O)cc2)C(=O)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
KMT2A Q03164 6/20 0.49
MEN1 O00255 5/20 0.49
GAA P10253 4/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 8/20 0.45
KDM4E B2RXH2 4/20 0.45
RECQL P46063 1/20 0.45
LMNA P02545 2/20 0.45
CA1 P00915 5/20 0.44
CA2 P00918 5/20 0.44
CA9 Q16790 5/20 0.44
CA12 O43570 4/20 0.44
TSHR P16473 2/20 0.43
NT5E P21589 1/20 0.43
CASP6 P55212 1/20 0.43
APP P05067 3/20 0.41
KAT8 Q9H7Z6 1/20 0.41
TDP1 Q9NUW8 3/20 0.40
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11871125 0.84 MEN1 (0.49) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL11682423 0.84 POLB (0.50) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL23718228 0.82 MAPT (0.61) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL2223232 0.81 MAPT (0.66) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL1715679 0.79 POLB (0.68) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL8003873 0.78 POLB (0.66) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL13597544 0.78 SHMT2 (0.46) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL3131292 0.78 POLB (0.66) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL4369241 0.77 KMT2A (0.65) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL124721 0.76 GAA (0.65) MAPTKMT2AMEN1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036208-B2 Methods for treating neurodegenerative disorders ALZHEON, INC. (US) 2024-07-16 US disclosed
US-12036208-B2 Methods for treating neurodegenerative disorders ALZHEON, INC. (US) 2024-07-16 US disclosed
US-11077095-B2 Methods for treating neurodegenerative disorders ALZHEON, INC. (US) 2021-08-03 US disclosed
EP-0445627-B1 Silver halide photographic light-sensitive materials FUJI PHOTO FILM CO LTD (JP) 1996-09-11 EP disclosed
EP-0445627-A1 Silver halide photographic light-sensitive materials FUJI PHOTO FILM CO., LTD. (JP) 1991-09-11 EP disclosed
US-4102688-A CONTAINING PYRAZOLO(3,4-B)PYRIDINE/3,6-DIONE MOIETY FUJI PHOTO FILM CO., LTD. (JP) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11077095-B2 Methods for treating neurodegenerative disorders NLN, CLN6, SNCA MAPT 9/4885KMT2A 3467/4885MEN1 4000/4885
US-12036208-B2 Methods for treating neurodegenerative disorders NLN, CLN6, SNCA MAPT 9/4885KMT2A 3467/4885MEN1 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.